Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells

Toxicology Letters

Volumn 232, Issue 2, 2015, Pages 481-489

  Zhang, Yao ^a,b   Sun, Miao ^c   Shi, Weiwei ^c   Yang, Qingling ^c   Chen, Changjie ^c   Wang, Zhiwei ^d   Zhou, Xin ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

^c BENGBU MEDICAL COLLEGE   (China)

^d SOOCHOW UNIVERSITY   (China)

Author keywords

APL; Arsenic trioxide; HL 60; HTERT; Promoter; Transcription

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MYC PROTEIN; MYOD PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR SP1; UPSTREAM STIMULATORY FACTOR 2; LUCIFERASE; ORGANOARSENIC DERIVATIVE; OXIDE; SMALL INTERFERING RNA; TELOMERASE; TERT PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HL 60 CELL LINE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HUMAN;

APOPTOSIS; ARSENICALS; CELL PROLIFERATION; DOWN-REGULATION; HL-60 CELLS; HUMANS; LUCIFERASES; OXIDES; RNA, SMALL INTERFERING; TELOMERASE; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84919799270     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.11.028     Document Type: Article

References (36)

1. Chou W.C., Dang C.V. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr. Opin. Hematol. 2005, 12:1-6.
2. Chou W.C., Hawkins A.L., Barrett J.F., Griffin C.A., Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J. Clin. Invest. 2001, 108:1541-1547.
3. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106:304-310.
4. de The H., Le Bras M., Lallemand-Breitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J. Cell Biol. 2012, 198:11-21.
5. Ding D., Zhou J., Wang M., Cong Y.S. Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. FEBS J. 2013, 280:3205-3211.
6. Ghaffari S.H., Momeny M., Bashash D., Mirzaei R., Ghavamzadeh A., Alimoghaddam K. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 2012, 17:198-206.
7. Gladych M., Wojtyla A., Rubis B. Human telomerase expression regulation. Biochem. Cell Biol. 2011, 89:359-376.
8. Grimwade D., Enver T. Acute promyelocytic leukemia: where does it stem from?. Leukemia 2004, 18:375-384.
9. Hassani S., Ghaffari S.H., Zaker F., Mirzaee R., Mardani H., Bashash D., Zekri A., Yousefi M., Zaghal A., Alimoghaddam K., Ghavamzadeh A. Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. Ann. Hematol. 2013, 92:1207-1220.
10. Holysz H., Lipinska N., Paszel-Jaworska A., Rubis B. Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol. 2013, 34:1371-1380.
11. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
12. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
13. Killela P.J., Reitman Z.J., Jiao Y., Bettegowda C., Agrawal N., Diaz L.A., Friedman A.H., Friedman H., Gallia G.L., Giovanella B.C., Grollman A.P., He T.C., He Y., Hruban R.H., Jallo G.I., Mandahl N., Meeker A.K., Mertens F., Netto G.J., Rasheed B.A., Riggins G.J., Rosenquist T.A., Schiffman M., Shih Ie M., Theodorescu D., Torbenson M.S., Velculescu V.E., Wang T.L., Wentzensen N., Wood L.D., Zhang M., McLendon R.E., Bigner D.D., Kinzler K.W., Vogelstein B., Papadopoulos N., Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6021-6026.
14. Kritharis A., Bradley T.P., Budman D.R. The evolving use of arsenic in pharmacotherapy of malignant disease. Ann. Hematol. 2013, 92:719-730.
15. Lengfelder E., Hofmann W.K., Nowak D. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Expert Rev. Anticancer Ther. 2013, 13:1035-1043.
16. Lengfelder E., Hofmann W.K., Nowak D. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions. Expert Rev. Anticancer Ther. 2013, 13:1035-1043.
17. Li J., Liu S.X. Changes of telomerase activity and hTERT mRNA expression in the process of apoptosis of HL-60 cells induced by arsenic sulfide. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi/Chin. J. Cell. Mol. Immunol. 2003, 19:595-597.
18. Li J., Cao Y.X., Hao J.X., Liu S.X. Comparison of the effect of arsenic sulfide on apoptosis and hTERT-mRNA expression in two leukemia cell lines. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi/Chin. J. Cell. Mol. Immunol. 2009, 25:900-902.
19. Liu J.X., Zhou G.B., Chen S.J., Chen Z. Arsenic compounds: revived ancient remedies in the fight against human malignancies. Curr. Opin. Chem. Biol. 2012, 16:92-98.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods 2001, 25:402-408.
21. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., Ferrara F., Fazi P., Cicconi L., Di Bona E., Specchia G., Sica S., Divona M., Levis A., Fiedler W., Cerqui E., Breccia M., Fioritoni G., Salih H.R., Cazzola M., Melillo L., Carella A.M., Brandts C.H., Morra E., von Lilienfeld-Toal M., Hertenstein B., Wattad M., Lubbert M., Hanel M., Schmitz N., Link H., Kropp M.G., Rambaldi A., La Nasa G., Luppi M., Ciceri F., Finizio O., Venditti A., Fabbiano F., Dohner K., Sauer M., Ganser A., Amadori S., Mandelli F., Dohner H., Ehninger G., Schlenk R.F., Platzbecker U. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 2013, 369:111-121.
22. Lu M.H., Liao Z.L., Zhao X.Y., Fan Y.H., Lin X.L., Fang D.C., Guo H., Yang S.M. hTERT-based therapy: a universal anticancer approach (Review). Oncol. Rep. 2012, 28:1945-1952.
23. Poole J.C., Andrews L.G., Tollefsbol T.O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001, 269:1-12.
24. Sanz M.A., Iacoboni G., Montesinos P. Acute promyelocytic leukemia: do we have a new front-line standard of treatment?. Curr. Oncol. Rep. 2013, 15:445-449.
25. Tallet A., Nault J.C., Renier A., Hysi I., Galateau-Salle F., Cazes A., Copin M.C., Hofman P., Andujar P., Le Pimpec-Barthes F., Zucman-Rossi J., Jaurand M.C., Jean D. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014, 33:3748-3752.
26. Tong H.Y., Jin J., Xu W.L., Qian W.B., Lin M.F. Study on the mechanisms of telomerase regulations during apoptosis of the human MDS-RAEB cell line MUTZ-1 cells induced by arsenic trioxide. Zhongguo Shi Yan Xue Ye Xue Za Zhi/Zhongguo Bing Li Sheng Li Xue Hui/J. Exp. Hematol./Chin. Assoc. Pathophysiol. 2005, 13:615-619.
27. Tun-Kyi A., Qin J.Z., Oberholzer P.A., Navarini A.A., Hassel J.C., Dummer R., Dobbeling U. Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann. Oncol. 2008, 19:1488-1494.
28. Wu Q., Wang R., Yang Q., Hou X., Chen S., Hou Y., Chen C., Yang Y., Miele L., Sarkar F.H., Chen Y., Wang Z. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget 2013, 4:1999-2009.
29. Xu L., Li S., Stohr B.A. The role of telomere biology in cancer. Ann. Rev. Pathol. 2013, 8:49-78.
30. Yaghmaie M., Mozdarani H., Alimoghaddam K., Ghaffari S.H., Ghavamzadeh A., Hajhashemi M. Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med. Oncol. 2012, 29:1209-1216.
31. Yang Q., Huang J., Wu Q., Cai Y., Zhu L., Lu X., Chen S., Chen C., Wang Z. Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br. J. Cancer 2014, 110:1958-1967.
32. Yang Q., Zhang F., Ding Y., Huang J., Chen S., Wu Q., Wang Z., Chen C. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br. J. Cancer 2014, 110:1288-1297.
33. Zekri A., Ghaffari S.H., Yousefi M., Ghanizadeh-Vesali S., Mojarrad M., Alimoghaddam K., Ghavamzadeh A. Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis. Mol. Cell. Endocrinol. 2013, 377:84-92.
34. Zhang Y., Zhao Y., Chen C. Suppressive role of arsenic trioxide in human telomerase activity in HL-60. J. Bengbu Med. Coll. 2003, 27:1-3.
35. Zhang Y., Gao X., Chen C., Yang Q. Alteration of reactive oxygen species, NF-kappaB, and C-IAP2 in apoptosis of HL-60 cells induced by arsenic trioxide. Caicinog. Tetratog. Mutagen. 2008, 20:371-375.
36. Zhou J. Arsenic trioxide: an ancient drug revived. Chin. Med. J. 2012, 125:3556-3560.